Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the target of a significant drop in short interest in March. As of March 13th, there was short interest totaling 9,838 shares, a drop of 48.4% from the February 26th total of 19,055 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 10,987 shares, the days-to-cover ratio is currently 0.9 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ATHE shares. Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Wednesday, January 21st. Zacks Research upgraded shares of Alterity Therapeutics to a “hold” rating in a report on Thursday, February 12th. Finally, Canaccord Genuity Group initiated coverage on shares of Alterity Therapeutics in a research report on Wednesday, December 17th. They issued a “speculative buy” rating on the stock. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Alterity Therapeutics currently has a consensus rating of “Hold”.

Institutional Trading of Alterity Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Twin Lakes Capital Management LLC lifted its position in shares of Alterity Therapeutics by 2,250.3% in the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after buying an additional 133,333 shares during the last quarter. Greenleaf Trust increased its holdings in shares of Alterity Therapeutics by 88.2% during the 3rd quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock worth $120,000 after acquiring an additional 15,000 shares during the last quarter. HB Wealth Management LLC bought a new stake in Alterity Therapeutics in the 3rd quarter valued at $220,000. Finally, Citadel Advisors LLC acquired a new stake in Alterity Therapeutics during the 3rd quarter valued at $83,000. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Stock Up 2.4%

NASDAQ ATHE opened at $3.41 on Thursday. The firm’s fifty day moving average price is $3.41 and its two-hundred day moving average price is $3.71. Alterity Therapeutics has a 1 year low of $2.52 and a 1 year high of $7.00.

Alterity Therapeutics (NASDAQ:ATHE) last released its quarterly earnings data on Friday, January 30th. The company reported ($0.18) earnings per share for the quarter. On average, analysts anticipate that Alterity Therapeutics will post -0.34 earnings per share for the current year.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.